Guerra MA

Language: Spanish
References: 17
Page: 27-30
PDF size: 103.46 Kb.

ABSTRACT

The use of plasma as a passive antibody transfer source has more than 100 years of experience. Passive immunity is a technique to acquire immediate and transient protection by administering specific antibodies against the pathogen in question, through plasma obtained from convalescent or immunized individuals. In recent times, the use of convalescent plasma has been associated with the emergence of new pathogens such as those causing SARS, MERS, Ebola and COVID, as the lack of effective treatments or effective vaccines requires the use of old but potentially effective medical procedures.

REFERENCES

1. Biographical: Emil von Behring. [Consultado julio 2020] Available in: www.nobelprize.org/prizes/medicine/1901/behring/biographical

2. Brown BL, McCullough J. Treatment of emerging viruses: convalescent plasma and Covid-19. Transfus Apher Sci. 2020; 59: 102790.

3. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016; 14: 152-157.

4. Fischer JC, Zänker K, Griensven M, Schneider M, Kindgen-Milles D, Trudo KW et al. The role of passive immunization in the era of SARS-Cov2: an update. Eur J Med Res. 2020; 25: 16.

5. Psaltopoulou T, Sergentanis TM, Pappa V, Politou M, Terpos E, Tsiodras S et al. The emerging role of convalescent plasma in the treatment of COVID-19. Hemasphere. 2020; 4 (3): e409.

6. Bozzo J, Jorquera JI. Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. Expert Rev Anti Infect Ther. 2017; 15 (6): 585-604.

7. Ye M, Fu D, Ren Y, Wang D, Shang F, Xia X et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020; 10/jmv.25882.

8. Hung IF, To KK, Lee CK, Chan K, Yan WW, Liu RR et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52 (4): 447-456.

9. Alzoughool F, Alanagreh L. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19. Int J Risk Saf Med. 2020; 31 (2): 47-51.

10. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117 (17): 9490-9496.

11. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020; 323 (16): 1582-1589.

12. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF et al. Effect of convalescent plasma on viral shedding and survival in patients with Coronavirus disease 2019. J Infect Dis. 2020; 222 (1): 38-43.

13. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA et al. Treatment of Coronavirus Disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol. 2020; 190 (8): 1680-1690.

14. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020; 19 (7): 102554.

15. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020; 72 (7): 1059-1063.

16. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80 (6): 607-613.

17. Li L, Tong X, Chen H, He R, Lv Q, Yang R et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion. 2020; 10.1111/trf.15918.